The pulsatile hormone the aging body forgets to send.

The pituitary releases growth hormone in pulses. Roughly six to twelve bursts per 24 hours, most of them clustered in the first half of slow-wave sleep, the rest scattered through the day. The amplitude and frequency of those pulses fall as people age. The somatotrope cells in the anterior pituitary do not vanish — they simply receive a smaller, less rhythmic upstream signal from the hypothalamus, where neurons of the arcuate nucleus secrete growth-hormone-releasing hormone.

Native human GHRH is a 44-amino-acid peptide with a half-life of less than ten minutes. Useful as a hypothalamic messenger; useless as a therapeutic. The molecule is too fragile.

Tesamorelin solved that problem with a single chemical modification. A trans-3-hexenoic-acid group was added to the N-terminus, which protects the peptide from cleavage by dipeptidyl peptidase-4 — the same enzyme that destroys native GLP-1. The modified molecule binds the GHRH receptor with comparable affinity to the native peptide and produces a pulsatile, physiologically patterned secretion of endogenous growth hormone. This is a different therapeutic strategy from administering recombinant growth hormone directly. The body's own feedback loops remain intact.

Origin

Tesamorelin was developed at Theratechnologies in Montreal beginning in the late 1990s. The Canadian biotech, working in collaboration with researchers at Massachusetts General Hospital and McGill University, focused initially on a difficult clinical problem: the visceral adiposity that develops in patients on long-term antiretroviral therapy for HIV. This is not ordinary central obesity. It is a metabolically distinct accumulation of intra-abdominal fat that does not respond well to caloric restriction or exercise.

Tesamorelin received FDA approval in 2010 for HIV-associated lipodystrophy under the trade name Egrifta. Steven Grinspoon and Takara Stanley at Massachusetts General Hospital have continued to publish on the molecule for fifteen years, including the 2024 efficacy data in patients on integrase-inhibitor regimens — the modern standard of HIV care.

Mechanism

Imagine a thermostat with a broken finger on the dial — the wires are intact, the heater works, but the controlling input is hesitant. Tesamorelin restores the input. It binds GHRH receptors on the somatotrope cells of the anterior pituitary, which release growth hormone in pulses. The pulses move through hepatic portal circulation, where the liver converts the signal into IGF-1. IGF-1 then exerts most of the downstream effects: nitrogen retention, lipolysis in selected fat depots, modulation of glucose handling, and effects on tissue repair and on the central nervous system.

What is unusual about tesamorelin is the tissue specificity of the resulting fat loss. Visceral adipose tissue — the omental and perirenal depots — appears to be selectively reduced. Subcutaneous fat is largely preserved. The mechanism is incompletely understood, but probably reflects differential expression of GH receptors and IGF-1 receptors across fat depots, combined with depot-specific differences in lipolytic enzyme activity.

The pulsatile pattern matters. Sustained, non-pulsatile elevation of growth hormone — the pattern produced by recombinant GH dosing — drives insulin resistance and IGF-1 elevation that may carry proliferative consequences. Pulsatile restoration via GHRH agonism preserves the negative-feedback loop. When IGF-1 rises, somatostatin tone rises, and the next pulse is dampened. The system regulates itself.

What the latest research shows

The clinical literature on visceral fat reduction has accumulated over fifteen years and is unusually robust for a peptide of this class. The phase 3 trials demonstrated approximately 15 percent reduction in visceral adipose tissue at 26 weeks compared with 5 percent placebo, with effects preserved through 52 weeks of continued therapy.

A 2017 paper in AIDS by Stanley and colleagues at Massachusetts General Hospital connected the visceral fat reduction to improved liver enzyme profiles. A subsequent 2019 Lancet HIV trial found that 12 months of tesamorelin reduced hepatic fat fraction by an absolute 4.1 percentage points in HIV-associated NAFLD — independent of body weight changes.

The 2024 AIDS paper from the same group is important because it answers a contemporary question: does the metabolic effect persist in patients on integrase-inhibitor regimens, the modern HIV-care standard? The answer was yes — visceral fat reduction was comparable to historical cohorts.

Beyond the obvious

The most underdiscussed finding in the tesamorelin literature came from the University of Washington School of Medicine in Seattle. Laura Baker and colleagues, publishing in Archives of Neurology in 2012, randomized 152 older adults — half cognitively normal, half with mild cognitive impairment — to 20 weeks of subcutaneous tesamorelin or placebo. The primary cognitive composite reflected executive function. Tesamorelin produced a favorable effect across the cohort, comparable in magnitude in MCI and healthy older adults. Executive function showed the strongest benefit; verbal memory trended favorably.

The effect was modest in absolute terms but mechanistically interesting. IGF-1 rose 117 percent — staying within the physiological range — and percent body fat dropped 7.4 percent. The mechanism by which restored GHRH-axis pulsatility benefits cortical executive function is not fully resolved, but candidate pathways include direct IGF-1 effects on hippocampal neurogenesis, improved cerebral glucose handling, and modulation of GABA-A signaling in the prefrontal cortex.

Twenty weeks of GHRH administration had favorable effects on cognition in both adults with MCI and healthy older adults.

A separate research line — pursued in animal models at the University of Tokyo and at the Karolinska Institute in Stockholm — has examined whether GHRH pulsatility restoration affects sleep architecture itself. Slow-wave sleep depth correlates with growth-hormone pulse amplitude, and the relationship is bidirectional.

Often studied alongside

Recent literature has paired tesamorelin with Ipamorelin in protocols dissecting the somatostatin-GHRH-ghrelin axis — tesamorelin acting at the receptor for the releasing factor, ipamorelin acting at a separate receptor for a different upstream regulator. Adjacent research at Yonsei University has examined tesamorelin alongside AOD-9604 in metabolic-syndrome animal models, where one compound restores GH-axis pulsatility and the other delivers the lipolytic C-terminal fragment of GH directly.

Practical considerations

Tesamorelin is administered subcutaneously, typically once daily, in research protocols that mirror the original phase 3 trial design. The pulsatile-secretion pattern that the molecule restores is most pronounced when dosing aligns with the natural overnight GH-pulse window — most studies dose in the evening before bedtime. Lyophilized material is stable below -20 °C for several years; reconstituted compound is stable at refrigeration for approximately seven days.

The half-life of tesamorelin itself is short — about 25 to 40 minutes — but the downstream IGF-1 elevation is sustained over 24 hours, reflecting the integration of multiple pulsatile bursts at the pituitary. None of the foregoing is medical advice. Precursor's compounds are research-use-only and not for human consumption.